Ernest Shingyan Wong
Profile
Ernest Shingyan Wong worked as President, Chief Executive Officer & Director at NervGen Pharma Corp.
from 2018 to 2019.
Prior to that, he was Vice President-Corporate Development at Cerecin, Inc. from 2016 to 2018.
He also worked as Head-Business Development at Life Molecular Imaging Ltd.
from 2013 to 2015 and as Vice President-Business Development at Agenus, Inc. and YM BioSciences, Inc. Dr. Wong holds a doctorate from the University of British Columbia, an undergraduate degree from Simon Fraser University, and an MBA from The University of Colorado.
Former positions of Ernest Shingyan Wong
| Companies | Position | End |
|---|---|---|
| NERVGEN PHARMA CORP. | Chief Executive Officer | 26/11/2019 |
Cerecin, Inc.
 Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Corporate Officer/Principal | 30/09/2018 |
| AGENUS INC. | Corporate Officer/Principal | 30/11/2015 |
Life Molecular Imaging Ltd.
 Life Molecular Imaging Ltd. Medical DistributorsDistribution Services Part of Old AMGL Interests 2 Ltd, Life Molecular Imaging Ltd. is a British company that wholesales diagnostic imaging solutions. The company is based in Warwick, UK. Life Molecular Imaging was founded in 2003. | Corporate Officer/Principal | 31/03/2015 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Training of Ernest Shingyan Wong
| University of British Columbia | Doctorate Degree |
| Simon Fraser University | Undergraduate Degree |
| The University of Colorado | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AGENUS INC. | Health Technology |
| NERVGEN PHARMA CORP. | Health Technology |
| Private companies | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Health Technology |
Life Molecular Imaging Ltd.
Life Molecular Imaging Ltd. Medical DistributorsDistribution Services Part of Old AMGL Interests 2 Ltd, Life Molecular Imaging Ltd. is a British company that wholesales diagnostic imaging solutions. The company is based in Warwick, UK. Life Molecular Imaging was founded in 2003. | Distribution Services |
- Stock Market
- Insiders
- Ernest Shingyan Wong